TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nektar Therapeutics ( (NKTR) ) has provided an update.
On November 8, 2025, Nektar Therapeutics presented new data from their Phase 2b REZOLVE-AD trial at the ACAAI Annual Scientific Meeting, showing that rezpegaldesleukin significantly improved asthma symptoms in patients with atopic dermatitis and a history of asthma. The trial results demonstrated statistically significant improvements in asthma control and atopic dermatitis disease control, supporting the potential of rezpegaldesleukin as a unique treatment option in these conditions. The findings indicate a promising future for rezpegaldesleukin in treating T-cell mediated inflammatory diseases, with plans to advance into Phase 3 studies.
The most recent analyst rating on (NKTR) stock is a Sell with a $30.00 price target. To see the full list of analyst forecasts on Nektar Therapeutics stock, see the NKTR Stock Forecast page.
Spark’s Take on NKTR Stock
According to Spark, TipRanks’ AI Analyst, NKTR is a Neutral.
Nektar Therapeutics’ overall stock score is primarily impacted by its challenging financial performance, characterized by significant losses and high leverage. While the earnings call provided positive insights into the company’s pipeline and financial health, these factors are overshadowed by the current financial instability. Technical analysis and valuation also present mixed signals, contributing to a cautious outlook.
To see Spark’s full report on NKTR stock, click here.
More about Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company focused on developing innovative therapies for autoimmune and inflammatory diseases. Their primary product, rezpegaldesleukin, is a first-in-class IL-2 pathway agonist designed to stimulate regulatory T cells, offering potential treatment for conditions like atopic dermatitis and alopecia areata.
Average Trading Volume: 1,021,134
Technical Sentiment Signal: Hold
Current Market Cap: $1.06B
Find detailed analytics on NKTR stock on TipRanks’ Stock Analysis page.